IVVD Key Statistics, Chart & Performance
The current stock price of IVVD is 2.525 USD. In the past month the price increased by 17.12%. In the past year, price increased by 539.76%.
IVVD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IVVD. When comparing the yearly performance of all stocks, IVVD is one of the better performing stocks in the market, outperforming 99.48% of all stocks.
IVVD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IVVD. While IVVD seems to be doing ok healthwise, there are quite some concerns on its profitability.
IVVD Financial Highlights
Over the last trailing twelve months IVVD reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 73.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.02% | ||
| ROE | -64.32% | ||
| Debt/Equity | 0 |
IVVD Forecast & Estimates
10 analysts have analysed IVVD and the average price target is 7.48 USD. This implies a price increase of 196.24% is expected in the next year compared to the current price of 2.525.
For the next year, analysts expect an EPS growth of 72.39% and a revenue growth 101.71% for IVVD
IVVD Ownership
IVVD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 383.15B | ||
| AMGN | AMGEN INC | 14.93 | 175.80B | ||
| GILD | GILEAD SCIENCES INC | 15.06 | 153.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.55 | 112.53B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.63 | 78.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 716.37 | 48.27B | ||
| INSM | INSMED INC | N/A | 34.37B | ||
| NTRA | NATERA INC | N/A | 32.92B | ||
| BIIB | BIOGEN INC | 10 | 24.55B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.52B | ||
| INCY | INCYTE CORP | 16.37 | 20.63B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.81 | 20.24B |
Related stock screener links
About IVVD
Company Profile
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in New Haven, Connecticut and currently employs 99 full-time employees. The company went IPO on 2021-08-06. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The firm delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The firm also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Company Info
INVIVYD INC
209 Church Street
New Haven CONNECTICUT US
Employees: 99
Phone: 17818190080
INVIVYD INC / IVVD FAQ
What does IVVD do?
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in New Haven, Connecticut and currently employs 99 full-time employees. The company went IPO on 2021-08-06. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The firm delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The firm also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
What is the current price of IVVD stock?
The current stock price of IVVD is 2.525 USD. The price decreased by -2.88% in the last trading session.
Does INVIVYD INC pay dividends?
IVVD does not pay a dividend.
What is the ChartMill technical and fundamental rating of IVVD stock?
IVVD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists IVVD stock?
IVVD stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for INVIVYD INC?
INVIVYD INC (IVVD) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for IVVD stock?
INVIVYD INC (IVVD) currently has 99 employees.